This study is testing an investigational drug called VYD2311 to see if it can help prevent COVID-19. VYD2311 is a monoclonal antibody, which means it's a type of protein designed to attach to the COVID-19 virus and stop it from infecting your cells. We are looking for adults and adolescents aged 12 to 100 years old to participate. You would receive either VYD2311 or a placebo (an inactive substance like saline) through shots into your muscle on Day 1, Day 30, and Day 60. The main goal is to see how well VYD2311 prevents symptomatic COVID-19 for 90 days after the first shot.

Study design

This interventional study plans to enroll 1770 participants. It compares different dosing schedules of VYD2311 against a placebo.

What's involved

Participants will receive three intramuscular injections on Day 1, Day 30, and Day 60. The study will monitor for symptomatic COVID-19 for 90 days.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for RT-PCR-confirmed symptomatic COVID-19 through Day 90.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.